MSCO 2013 Annual Meeting and Award Presentation
"The Impact of Genomic Testing on the
Treatment of Lung Cancer"
Bruce E. Johnson, MD
Dana Farber Cancer Institute
Thursday, November 7, 2013
Click HERE for the Registration Brochure
After participating in this activity, attendees should be able to:
- Identify the common genomic changes in lung cancers which are potential therapeutic targets
- Assess the efficacy of different targeted agents for specific genomic changes in lung cancers
- Apply the findings about the efficacy of targeted agents for ordering genomic testing in appropriate patients with lung cancer
The Massachusetts Medical Society designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the Joint Sponsorship of the Massachusetts Medical Society and the Massachusetts Society of Clinical Oncologists.
The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
For questions in regard to this event, please contact Lynda Layer at (781) 434-7317 or e-mail firstname.lastname@example.org.